Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

Ver Toda la documentación

D-915

Supelco

Desalkylflurazepam solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C15H10ClFN2O
Número de CAS:
2886-65-9
Peso molecular:
288.70
EC Number:
200-659-6
MDL number:
MFCD00083443
UNSPSC Code:
41116107
NACRES:
NA.24

grade

certified reference material

Quality Level

300

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

drug control

Narcotic Licence Schedule B (Switzerland)

concentration

1.0 mg/mL in methanol

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

clinical testing

format

single component solution

storage temp.

−20°C

SMILES string

Fc1ccccc1C2=NCC(=O)Nc3ccc(Cl)cc23

InChI

1S/C15H10ClFN2O/c16-9-5-6-13-11(7-9)15(18-8-14(20)19-13)10-3-1-2-4-12(10)17/h1-7H,8H2,(H,19,20)

InChI key

UVCOILFBWYKHHB-UHFFFAOYSA-N

General description

Desalkylflurazepam, also known as N-desalkyl-2-oxoquazepam, is a long-acting metabolite of the benzodiazepine drug flurazepam. Flurazepam is sold unde the trade names Dalmane and Dalmadorm for the treatment of mild to moderate insomnia. This Certified Spiking Solution® is suited for use in LC/MS or GC/MS applications for clinical toxicology, forensic analysis or urine drug testing.

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

related product

Referencia del producto
Descripción
Precios

D-924

Desalkylflurazepam-d4 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

F-003

Flurazepam solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

F-901

2-Hydroxyethylflurazepam solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

F-902

2-Hydroxyethylflurazepam solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

H-919

2-Hydroxyethylflurazepam-d4 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

H-923

2-Hydroxyethylflurazepam-d4 solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

signalword

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

target_organs

Eyes,Central nervous system

Storage Class

3 - Flammable liquids

wgk_germany

WGK 2

flash_point_f

49.5 °F - closed cup

flash_point_c

9.7 °C - closed cup

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

J Hilbert et al.
Drug metabolism and disposition: the biological fate of chemicals, 12(4), 452-459 (1984-07-01)
The disposition of 14C-quazepam (7-chloro-(2,2,2-trifluoroethyl) [5-14C]-5-o-fluorophenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-thione), a new benzodiazepine hypnotic, was studied in hamsters and mice after iv and po dosing. In both species, quazepam was rapidly absorbed, as indicated by the plasma Cmax being reached within 1 hr of
Y Sakai et al.
Japanese journal of pharmacology, 37(4), 373-379 (1985-04-01)
A new benzodiazepine compound, ethyl loflazepate (ethyl-7-chloro-2,3-dihydro-5-(2-fluorophenyl)-2-oxo-1H,1,4- benzodiazepine-3-carboxylate; CM6912) was studied using in vitro experimental systems for its displacement activity on 3H-diazepam binding to the synaptosomal membrane fraction of rat cerebrum and potentiating action on GABA. CM6912 inhibited the specific
S K Gupta et al.
Pharmaceutical research, 5(6), 365-368 (1988-06-01)
A reverse-phase liquid chromatographic method is described for simultaneous quantification of quazepam, and two of its metabolites, 2-oxoquazepam and N-desaklyl-2-oxoquazepam. The method uses a solid-phase extraction procedure to prepare plasma samples. After extraction, the methanolic extract is evaporated; the residue
J M Hilbert et al.
Clinical pharmacology and therapeutics, 36(4), 566-569 (1984-10-01)
The kinetics of quazepam, a benzodiazepine hypnotic, was studied in 10 geriatric subjects. Each received one 15-mg tablet of quazepam. Blood samples were collected before and at specified times (up to 672 hr) after dosing. Plasma concentrations of quazepam and
K Schaffler et al.
Arzneimittel-Forschung, 39(2), 276-283 (1989-02-01)
To assess pharmacodynamic and pharmacokinetic properties of acute, subchronic and withdrawn quazepam, a single-blind, longitudinal study was run in eight male, healthy young volunteers. The design covered a 1-week placebo run-in period, a period with daily oral night-time administration of
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico